Pulse Biosciences, Inc. (FRA:6L8)

Germany flag Germany · Delayed Price · Currency is EUR
21.00
-0.40 (-1.87%)
Last updated: Feb 20, 2026, 8:01 AM CET
Market Cap1.24B -14.8%
Revenue (ttm)298.10K
Net Income-61.99M
EPS-0.92
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume13
Open21.00
Previous Close21.40
Day's Range21.00 - 21.00
52-Week Range10.80 - 21.40
Betan/a
RSI73.09
Earnings DateFeb 19, 2026

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2014
Employees 75
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6L8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements